1820583-17-2

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
(7aS)-3-phenyltetrahydro-3H,5H-pyrrolo[1,2-c]oxazol-5-one is used as a potential drug candidate for various medical conditions due to its promising biological activities and pharmacological properties. Its unique molecular structure allows it to be a valuable building block for the synthesis of new chemical compounds with potential medicinal benefits.
Used in Synthesis of New Chemical Compounds:
In the field of medicinal chemistry, (7aS)-3-phenyltetrahydro-3H,5H-pyrrolo[1,2-c]oxazol-5-one is used as a key intermediate for the synthesis of novel chemical compounds. Its structural features make it a versatile component in the development of new drugs with potential therapeutic applications.

Upstream product

• 100-52-7 benzaldehyde 
• 17342-08-4 (S)-Pyroglutaminol 
• 62400-75-3 pyroglutamol 
• 66673-40-3 (R)-5-hydroxymethylpyrrolidin-2-one 
• 68766-96-1 ethyl (R)-2-pyrrolidone-5-carboxylate 
• 13107-55-6 D-glutamic acid diethyl ester 
• 6893-26-1 D-Glutamic acid 
• 4931-66-2 methyl (S)-pyroglutamate 
• 6525-53-7 L-glutamic acid dimethyl ester 
• 98-79-3 L-Pyroglutamic acid 
• 104-15-4 toluene-4-sulfonic acid 
• 7149-65-7 ethyl (S)-pyroglutamate 
• 74936-93-9 (S)-5-oxopyrrolidine-2-carbonyl chloride 
• 56-86-0 L-glutamic acid 

Downstream Products

• 134107-65-6 (3R,7aS)-3-phenyl-3,7a-dihydro-1H-pyrrolo[1,2-c]oxazol-5-one 
• 134107-63-4 (+)-(2R,5S,7S)-1-aza-3-oxa-2-phenyl-7-(phenylselenenyl)bicyclo<3.3.0>octan-8-one 
• 134037-91-5 (2R,5S)-1-aza-3-oxa-2-phenyl-7-(4'-nitrophenyl(hydroxy)methyl)bicyclo<3.3.0>octan-8-one 
• 138231-09-1 (+)-(2R,5S,7R)-1-aza-3-oxa-2-phenyl-7-(4'-nitrophenylmethyl)bicyclo<3.3.0>octan-8-one 
• 138078-56-5 (+)-(2R,5S,7S)-1-aza-3-oxa-2-phenyl-7-(4'-nitrophenylmethyl)bicyclo<3.3.0>octan-8-one 
• 195818-96-3 (+)-(2R,5S,7R)-1-aza-3-oxa-2-phenyl-7,7-di(phenylselenenyl)bicyclo<3.3.0>octan-8-one 
• 176243-34-8 (2R,5S,7R)-1-aza-3-oxa-8-oxo-2-phenyl-7-iodobicyclo[3.3.0]octane 
• 176484-87-0 (2R,5S,7S)-1-aza-3-oxa-8-oxo-2-phenyl-7-iodobicyclo[3.3.0]octane 
• 569679-06-7 3-(tert-butyl) 2-methyl (1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2,3-dicarboxylate 
• 220623-24-5 (1R,2S,5S,6R)-3-aza-3-<(tert-butyl)oxycarbonyl>-6-methoxycarbonylbicyclo<3.1.0>hexyl-2-methanol 
• 220623-25-6 (1R,2S,5S,6R)-3-aza-3-<(tert-butyl)oxycarbonyl>-6-methoxycarbonylbicyclo<3.1.0>hexyl-2-carboxylic acid 

Relevant academic research and scientific papers

Synthesis of [(3S,5R)-3-Hydroxy-5-methylpiperidin-1-yl](2-methylpyridin-3-yl)methanone

Abstract: There remain challenges for effectively synthesizing heterocycles containingboth piperidine and pyridine rings, mainly due to the inefficient syntheticprocess mostly requiring long reaction times. This paper reports a simple andefficient method

INHIBITORS OF APOL1 AND METHODS OF USING SAME

The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).

ANTIMICROBIAL COMPOUNDS AND METHODS

The invention is directed to compounds that are active as antibacterial agents. The invention compounds are active against gram-positive and gram-negative bacteria and can be used to treat infections caused by gram-positive and gram-negative bacteria. Also disclosed are processes and intermediates for making the compounds.

KRAS G12C INHIBITORS

The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

BENZIMIDAZOLE-LINKED INDOLE COMPOUND ACTING AS NOVEL DIVALENT IAP ANTAGONIST

The present invention discloses a benzimidazole-linked indole compound acting as novel divalent IAP antagonist, specifically disclosing the compound shown in fomulas (I) or a pharmaceutically acceptable salt thereof.

ANTI-EGFR ANTIBODY DRUG CONJUGATES

The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.

NITROGEN-CONTAINING HETEROCYCLIC AMIDE COMPOUND AND PHARMACEUTICAL USE THEREOF

PROBLEM TO BE SOLVED: To provide a nitrogen-containing heterocyclic amide compound having pyruvate dehydrogenase kinase inhibitory activity, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same. SOLUTION: The present invention provides a compound of formula [I-a] or formula [II], or a pharmaceutically acceptable salt thereof (a bond of a dotted line: a single bond or a double bond. X1: C, N, O. X2: C, N. R1a: C1-4 alkyl, C1-4 alkyl carbonyl. R2: halogen, cyano, C1-4 alkyl. A1-A7: C, N, O. A8: C, N. R3, R4: H, C1-4 alkyl. Cy1: C4-6 cycloalkyl or the like. Cy2: C3-6 cycloalkyl or the like. m, t, w: 0, 1. n, r, v: 0, 1, 2.) SELECTED DRAWING: None COPYRIGHT: (C)2019,JPOandINPIT

Compounding method for LCZ696 midbody

The invention discloses a compounding method for a LCZ696 midbody. The compounding route is as follows: wherein R1 is Me, Et or i-Pr; X is Cl, Br or I; R2 is Ms, Ts or Tf. According to the compounding method for the LCZ696 midbody disclosed by the invention, the methylating difficulty is reduced, the midbody is configured and overturned through the consequent reaction, the proportion of the required configuration is greatly increased, the product yield, purity and use ratio are increased and the industrial large-scale production is benefited.

ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES

The invention relates to anti-CD98 antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

ANTI-EGFR ANTIBODY DRUG CONJUGATES

The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.